CAR T-cell Therapy | Specialty

Key AE Management Strategies in Place for CAR T-Cell Therapy in Hematologic Cancers

February 29th 2020

With the main toxicities associated with CAR T-cell therapy being cytokine release syndrome and neurotoxicity, a multidisciplinary approach is vital to providing inclusive care to patients receiving this type of treatment.

Dr. Tzachanis on Data With Lisocabtagene Maraleucel in Lymphoma

February 28th 2020

Dimitrios Tzachanis, MD, PhD, discusses data with lisocabtagene maraleucel (liso-cel) in large B-cell lymphoma, as well as the differences between axicabtagene ciloleucel (axi-cel; Yescarta) and tisagenlecleucel (Kymriah).

Dr. Adusumilli on the Development of CAR T Cells in Solid Tumors

February 28th 2020

Prasad S. Adusumilli, MD, FACS, discusses the current role of chimeric antigen receptor T-cell therapy as treatment of patients with solid tumors and how this is evolving compared to CAR T cells in hematologic malignancies.

Adding CAR T-Cell Therapy to the Electronic Medical Record

February 28th 2020

Andrea Price, APN, discusses adding CAR T-cell therapy to the electronic medical record.

Axi-Cel Toxicity in LBCL May Be Alleviated With Earlier Steroid Use

February 22nd 2020

Early steroid intervention has the potential to reduce the severity of adverse events associated with axicabtagene ciloleucel in patients with refractory large B-cell lymphoma, according to an analysis of the phase I/II ZUMA-1 trial.

Dr. Jain on Hematopoietic Recovery Following CAR T-Cell Therapy

February 20th 2020

Tania Jain, MBBS, discusses hematopoietic recovering following treatment with a chimeric antigen receptor T-cell therapy in patients with hematologic malignancies.

Dr. Abramson on the TRANSCEND NHL 001 Trial in Large B-Cell Lymphoma

February 15th 2020

Jeremy S. Abramson, MD, discusses the results of the multicenter phase I TRANSCEND NHL 001 study evaluating the safety and efficacy of lisocabtagene maraleucel in relapsed/refractory large B-cell lymphoma.

FDA Grants Priority Review to Liso-Cel in Large B-Cell Lymphoma

February 13th 2020

The FDA has granted a priority review designation to a biologics license application for the anti-CD19 CAR T-cell therapy lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma after at least 2 prior therapies.

Dr. Kansagra on Remaining Questions With CAR T-Cell Therapy in Multiple Myeloma

February 13th 2020

Ankit Kansagra, MD, discusses remaining questions with CAR T-cell therapy in multiple myeloma.

JNJ-4528 Boasts High Response Rate in Relapsed/Refractory Myeloma

February 6th 2020

Deepu Madduri, MD, discusses the results of the CARTITUDE-1 trial and the next phase of development with JNJ-4528.

Dr. Voorhees on the Role of CAR T-Cell Therapy in Multiple Myeloma

February 5th 2020

Peter Voorhees, MD, discusses the role of CAR T-cell therapy in multiple myeloma.

Dr. Kansagra on Expanding Role of CAR T-Cell Therapy in Lymphoma and Multiple Myeloma

February 4th 2020

Ankit Kansagra, MD, discusses the expanding role of CAR T-cell therapy in lymphoma and multiple myeloma.

CAR T-Cell Products Among Top Advances in Non-Hodgkin Lymphoma

February 1st 2020

Praveen Ramakrishnan, MD, spotlights some of the exciting data recently presented across the spectrum of non-Hodgkin lymphoma treatment.

Priority Review in RET Fusion+ NSCLC and Thyroid Cancers, Breakthrough Status in MDS, and More

January 30th 2020

MCL: FDA Approval of a Second-Generation BTK Inhibitor

January 30th 2020

CAR T-Cell Therapy and the Future Management of MCL

January 30th 2020

Mantle Cell Lymphoma: Chemotherapy-Free Treatment Options

January 30th 2020

BTK Inhibitors in MCL: AEs, Specificity, and Interactions

January 30th 2020

Selecting a BTK Inhibitor for Mantle Cell Lymphoma

January 30th 2020

Updates in Management of Mantle Cell Lymphoma

January 30th 2020